GWN Securities Inc. Takes Position in Edwards Lifesciences Co. (NYSE:EW)

GWN Securities Inc. acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 9,525 shares of the medical research company's stock, valued at approximately $658,000.

Several other institutional investors have also modified their holdings of EW. Abacus Planning Group Inc. grew its position in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after buying an additional 140 shares during the last quarter. Bowman & Co S.C. boosted its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after acquiring an additional 148 shares in the last quarter. Moors & Cabot Inc. grew its holdings in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after acquiring an additional 152 shares during the last quarter. Pegasus Asset Management Inc. raised its position in shares of Edwards Lifesciences by 0.4% during the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after purchasing an additional 159 shares during the period. Finally, Mount Yale Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock valued at $634,000 after purchasing an additional 162 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EW has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research report on Thursday, February 13th. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Evercore ISI cut their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Up 0.0 %

Shares of Edwards Lifesciences stock traded up $0.01 during midday trading on Thursday, reaching $70.91. 4,052,919 shares of the company's stock traded hands, compared to its average volume of 4,532,147. The company has a market cap of $41.69 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company's 50 day simple moving average is $71.54 and its 200 day simple moving average is $70.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock valued at $3,715,776 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.